Attia Ismail A, El-Gizawy Sanaa A, Fouda Medhat A, Donia Ahmed M
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta, Egypt.
AAPS PharmSciTech. 2007 Dec 14;8(4):E106. doi: 10.1208/pt0804106.
The purpose of this research was to prepare acyclovir niosomes in a trial to improve its poor and variable oral bioavailability. The nonionic surfactant vesicles were prepared by the conventional thin film hydration method. The lipid mixture consisted of cholesterol, span 60, and dicetyl phosphate in the molar ratio of 65:60:5, respectively. The percentage entrapment was approximately 11% of acyclovir used in the hydration process. The vesicles have an average size of 0.95 microm, a most probable size of 0.8 microm, and a size range of 0.4 to 2.2 microm. Most of the niosomes have unilamellar spherical shape. In vitro drug release profile was found to follow Higuchi's equation for free and niosomal drug. The niosomal formulation exhibited significantly retarded release compared with free drug. The in vivo study revealed that the niosomal dispersion significantly improved the oral bioavailability of acyclovir in rabbits after a single oral dose of 40 mg kg(-1). The average relative bioavailability of the drug from the niosomal dispersion in relation to the free solution was 2.55 indicating more than 2-fold increase in drug bioavailability. The niosomal dispersion showed significant increase in the mean residence time (MRT) of acyclovir reflecting sustained release characteristics. In conclusion, the niosomal formulation could be a promising delivery system for acyclovir with improved oral bioavailability and prolonged drug release profiles.
本研究的目的是制备阿昔洛韦脂质体,以改善其较差且不稳定的口服生物利用度。通过传统的薄膜水化法制备非离子表面活性剂囊泡。脂质混合物由胆固醇、司盘60和十六烷基磷酸酯组成,摩尔比分别为65:60:5。包封率约为水化过程中所用阿昔洛韦的11%。囊泡的平均大小为0.95微米,最可能大小为0.8微米,大小范围为0.4至2.2微米。大多数脂质体呈单层球形。体外药物释放曲线表明游离药物和脂质体药物均符合 Higuchi 方程。与游离药物相比,脂质体制剂的释放明显延迟。体内研究表明,单次口服剂量为40 mg kg(-1) 后,脂质体分散体显著提高了阿昔洛韦在兔体内的口服生物利用度。脂质体分散体中药物相对于游离溶液的平均相对生物利用度为2.55,表明药物生物利用度增加了两倍多。脂质体分散体显示阿昔洛韦的平均驻留时间 (MRT) 显著增加,反映了缓释特性。总之,脂质体制剂可能是一种有前景的阿昔洛韦给药系统,具有改善的口服生物利用度和延长的药物释放曲线。